title: Endovascular treatment of mesenteric ischemia.
abstract: OBJECTIVE
  Our goal was to describe a single-center's experience in managing acute and chronic mesenteric ischemia with endovascular therapies.
  
  
  BACKGROUND
  Open surgical revascularization has been considered the historical gold standard treatment for mesenteric ischemia though it poses considerable morbidity and mortality risk. An aging population with increased comorbidities makes endovascular treatment a more attractive treatment option.
  
  
  METHODS
  Consecutive subjects receiving percutaneous mesenteric interventions for acute and chronic mesenteric ischemia from 2004 to 2010 were identified retrospectively. Information on comorbidities, symptoms, screening tests, procedural outcomes, and follow up was obtained.
  
  
  RESULTS
  Thirty-one patients received percutaneous mesenteric interventions during this period. The mean age of the population was 65.0 years with roughly equal proportions of males (48.4%) and females (51.6%). Traditional cardiovascular risk factors were highly prevalent (hypertension 45.2%, diabetes 25.8%, dyslipidemia 38.7%, nicotine use 45.2%). Procedural success was 93.5%; no periprocedural complications were reported. During a mean follow up of 13 months, 16.1% required repeat revascularization and 22.6% died. Endovascular treatment of acute mesenteric ischemia was successful (n = 8) and no patient required open surgical revascularization acutely or during follow-up.
  
  
  CONCLUSIONS
  Endovascular treatment of mesenteric ischemia is a safe and effective therapy with acceptable long-term results. Our experience with acute mesenteric ischemia suggests that percutaneous treatment may be an effective alternative to surgical revascularization in appropriately selected patients.
authors.affiliation: Department of Internal Medicine, Section of Cardiovascular Disease, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73190, USA. beau-hawkins@ouhsc.edu
authors.forename: Beau M
authors.initials: BM
authors.lastname: Hawkins
authors.forename: Zeeshan
authors.initials: Z
authors.lastname: Khan
authors.forename: Mazen S
authors.initials: MS
authors.lastname: Abu-Fadel
authors.forename: J Emilio
authors.initials: JE
authors.lastname: Exaire
authors.forename: Jorge F
authors.initials: JF
authors.lastname: Saucedo
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Hennebry
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002908:Chronic Disease; D018572:Disease-Free Survival; D057510:Endovascular Procedures / Q000009:adverse effects / Q000295:instrumentation / Q000401:mortality; D005260:Female; D006801:Humans; D007511:Ischemia / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D053208:Kaplan-Meier Estimate; D008297:Male; D065666:Mesenteric Ischemia; D008875:Middle Aged; D009825:Oklahoma; D018579:Patient Selection; D011859:Radiography; D012189:Retrospective Studies; D015607:Stents; D013997:Time Factors; D016896:Treatment Outcome; D014652:Vascular Diseases / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*